アセチルジゴキシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/07/27 22:39:44」(JST)
[Wiki en表示]
| This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (August 2007) (Learn how and when to remove this template message) |
α-Acetyldigoxin|
|
| Clinical data |
|---|
| AHFS/Drugs.com |
International Drug Names |
|---|
Routes of
administration |
Oral |
|---|
| ATC code |
|
|---|
| Pharmacokinetic data |
|---|
| Bioavailability |
90%(Oral) |
|---|
| Protein binding |
20–30% |
|---|
| Elimination half-life |
40h |
|---|
| Identifiers |
|---|
IUPAC name
- [6-[6-[ [6-[ [12,14-dihydroxy-10,13-dimethyl-17-
|
| CAS Number |
|
|---|
| PubChem CID |
|
|---|
| ChemSpider |
|
|---|
| UNII |
|
|---|
| ECHA InfoCard |
100.024.414 |
|---|
| Chemical and physical data |
|---|
| Formula |
C43H66O15 |
|---|
| Molar mass |
822.975 g/mol |
|---|
| 3D model (JSmol) |
|
|---|
SMILES
O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](OC(=O)C)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6
|
InChI
InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1 Y
Key:HWKJSYYYURVNQU-DXJNJSHLSA-N Y
|
| (verify) |
|---|
α-Acetyldigoxin is a cardiac glycoside. It is an acetyl derivative of digoxin and an isomer of β-acetyldigoxin. It increases the contractility of the heart by its positive inotropic effect on cardiac muscle. The effects of α-acetyldigoxin begin 3–4 hours after administration, and maximize after 6–8 hours. It is prescribed for congestive chronic cardiac failure class II, III and IV.
External links
- α-acetyldigoxin in the ChemIDplus database
Cardiac glycosides (C01A) |
|---|
| Bufadienolides | | Bufo |
- Arenobufagin
- Bufotalin
- Cinobufagin
- Marinobufagin
|
|---|
| Scilla |
- Proscillaridin
- Scilliroside
|
|---|
|
|---|
| Cardenolides | | Digitalis |
- Acetyldigitoxin
- Acetyldigoxin
- Digitoxin#
- Digoxin#
- Lanatoside C
- Deslanoside
- Metildigoxin
- Gitoformate
|
|---|
| Kalanchoe | |
|---|
| Strophanthus |
- Ouabain (g-Strophanthin)
- k-Strophanthin
- Cymarin
|
|---|
| Thevetia | |
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
English Journal
- Prescribing potentially inappropriate medication (PIM) in Germany's elderly as indicated by the PRISCUS list. An analysis based on regional claims data.
- Schubert I1, Küpper-Nybelen J, Ihle P, Thürmann P.
- Pharmacoepidemiology and drug safety.Pharmacoepidemiol Drug Saf.2013 Jul;22(7):719-27. doi: 10.1002/pds.3429. Epub 2013 Apr 12.
- PURPOSE: The aim of this study was to estimate the prevalence of potentially inappropriate medication (PIM) in the elderly as indicated by Germany's recently published list (PRISCUS) and to assess factors independently associated with PIM prescribing, both overall and separately for therapeutic grou
- PMID 23585247
- Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list.
- Amann U1, Schmedt N, Garbe E.
- Deutsches Ärzteblatt international.Dtsch Arztebl Int.2012 Feb;109(5):69-75. doi: 10.3238/arztebl.2012.0069. Epub 2012 Feb 3.
- BACKGROUND: The PRISCUS list of potentially inappropriate medications (PIM) for the elderly was published in 2010 and is the first systematically constructed list of this type in Germany. The aim of the present study is to estimate the baseline prevalence of the prescribing of PIM, as defined by the
- PMID 22368709
- Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency.
- Sukoyan GV1, Gongadze NV.
- Bulletin of experimental biology and medicine.Bull Exp Biol Med.2011 Mar;150(5):610-3.
- The therapeutic action of adenocine during cardiac insufficiency (heart failure) caused by ischemic (stenosis) or reperfusion (removal of ligature) injury to the myocardium prevents depletion of ATP, the major energy source for myocytes in the right and left ventricles, and a drop in NAD/NADH ratio.
- PMID 22235397
Japanese Journal
- P-glycoprotein-mediated transport of digitoxin, alphamethyldigoxin and beta-acetyldigoxin
- PAULI MAGNUS C.
- Naunyn. Schmiedebergs. Arch. Pharmacol. 363, 337-343, 2001
- NAID 80012671633
- 強心配糖体の注入毒性による致死量検定ならびに作用持続測定
- 福田 保
- 日本薬理学雑誌 70(1), 39-46, 1974
- … A，α-acetyldigoxin，β-acetyldigoxin，digoxinおよびdigitoxinの最小致死量を検定した．2)モルモットの左心房内にadenosine20μgを注入すると，bradycardiaとheart blockを生ずる．この作用を強心配糖体が増強する特性を利用して，強心配糖体の作用持続時間を測定し，これによって消失率(%LD)を計算した結果は，ouabain;is，proscillaridin A;14，β-acetyldigoxin;9，α-acetyldigoxin;6，digoxin; …
- NAID 130000757976
Related Links
- Acetyldigoxin is a medicine available in a number of countries worldwide. A list of US medications equivalent to Acetyldigoxin is available on the Drugs.com website. ... Drugs.com provides accurate and independent information on ...
- acetyldigoxin (countable and uncountable, plural acetyldigoxins) Wikipedia has an article on: acetyldigoxin Wikipedia A cardiac glycoside, an acetyl derivative of digoxin. Translations [edit] drug Finnish: asetyylidigoksiini https://en" ...